NCT03940378Unknown3 期
The Efficacy of Levamisole Hcl in Advanced Intrahepatic Cholangiocarcinoma . A Multicenter, Open, Randomized, Prospective Study
The First Affiliated Hospital of Zhengzhou University1 个研究点 分布在 1 个国家目标入组 152 人开始时间: 2019年2月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 152
- 试验地点
- 1
- 主要终点
- Progression-free Survival
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of Levamisole Hcl in the treatment of patients with advanced intrahepatic cholangiocarcinoma.
详细描述
Intrahepatic cholangiocarcinoma(ICC) ,a kind of Hepatocellular carcinoma, is the sixth most common cancer and thesecond leading cause of cancer-related deaths in the world.Currently, Surgical resection is still the main treatment methods of early the ICC, but that is high recurrent . Levamisole Hcl is a broad spectrum of intestinal worm medicine, our previous study have found levamisole could significantly promote the apoptosis of bile duct cancer cells, restrain the progress of the bile duct carcinoma in clinic and prolong survival time.This drug is applicable to a variety of reasons caused by intrahepatic bile duct carcinoma and extrahepatic bile duct carcinoma,so we carry out the study to evaluate the efficacy and safety of Levamisole Hcl in the treatment of patients with advanced intrahepatic cholangiocarcinoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ages 18-65 years
- •The diagnosis of ICC: in accordance with "diagnostic and treating standards on primary liver cancer" or histological/cytological diagnosis of primary liver cancer
- •Un-resectable HCC : patients with developing primary liver cancer of Barcelona stage(BCLC) B; multiple nodules (less than 5, the total diameter of less than 20 cm), no invasion, no symptoms;refusing open surgical treatment and volunteering for the treatment
- •The First-line system therapy failure (or residual lesion) from the group of this study a signed informed consent (time) for 2 weeks or more basic returned to normal and adverse events (NCI CTCAE Ⅰ level or less);
- •Child-Pugh liver function class A/B(score: ≤7)
- •Performance status 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale in one week before admission
- •Estimated survival time > 3 months
- •HBV DNA#2000 IU/ml#10^4 copies/ml); or HBV DNA≥2000 IU/ml and are accepting effective antiviral therapy
- •The major organ function is normal. that is meeting the following standards:
- •Blood routine examination: (No blood transfusion, no G-CSF and no medication were corrected within 14 days before screening)
- •a.HB≥80g/L# b.ANC≥1.5×109/L#c.PLT≥50×109/L#
- •Biochemical examination: (ALB was not transfused within 14 days before screening) a.ALB ≥29 g/L# b.ALT#AST<5ULN#c.TBIL ≤3ULN#d.creatinine
- •1.5ULN( albumin and bilirubin, two indicators of Child-Pugh liver function class, can only have one for 2 points)
- •For women of childbearing age, the results of serum/urine pregnancy tests must be negative within 7 days before initiation of treatment. All men and women who participate in the study have to take reliable contraceptive measures within the trial and eight weeks after the trial is completed
- •volunteers must signed informed consent
排除标准
- •With a history of alimentary tract hemorrhage or a definite tendency of gastrointestinal bleeding, such as varices of fundus of stomach and esophagus with bleeding risk; local active ulcer lesions; fecal occult blood ≥#++#
- •Patients with hepatobiliary cell carcinoma, mixed cell carcinoma or lamellar cell carcinoma; in the past (within 5 years) or at the same time suffering from other untreated malignant tumors; excluding cured basal cell carcinoma and carcinoma in situs of cervix
- •Patients who are undergoing liver transplantation or have a history of organ transplantation(excluding the patient who has undergone liver transplantation before)
- •Patients with an allergic history of Levamisole Hydrochloride and Anlotinib Hydrochloride Capsules
- •The blood pressure can not be reduced to the normal range by the antihypertensive drug treatment in patients with hypertension(systolic pressure#140 mmHg, diastolic pressure#90 mmHg)
- •Patients with myocardial ischemia or myocardial infarction over grade II or a poorly controlled arrhythmia (including QTc interval: men ≥ 450 ms; women ≥ 470 ms)
- •Cardiac functional insufficiency of grade III to IV according to NYHA standard; echocardiography: LVEF#50%
- •Many factors that influence oral medication, such as unable to swallow; chronic diarrhea; intestinal obstruction; the situations which significantly affect the use and absorption of drugs
- •Abdominal fistula, gastrointestinal perforation, or abdominal abscess occurred within 28 days before participating the study
- •Dysfunction of blood coagulation(INR#2.0 or PT# 16s#APTT > 43s#TT > 21s#Fbg < 2g/L), having a tendency to bleed or undergoing thrombolysis or anticoagulant therapy; ascites with clinical symptoms, that is requiring therapeutic abdominal paracentesis or drainage or Child-Pugh score ≥2
- •Objective evidence of pulmonary fibrosis history, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug associated pneumonia, and severe lung function impairment in the past and at present
- •Urine routine showed that urine protein ≥++ or the urine protein in 24 hours#1.0 g
- •Patients who have been treated with potent CYP3A4 inhibitors (ketoconazole, itraconazole, voriconazole, ritonavir, clarithromycin, telithromycin, troleandomycin, erythromycin, cimetidine and so on) within 28 days before participating the study, or potent CYP3A4 inducers (dexamethasone, phenytoin, rifampin, rifabutin, carbamazepine, phenobarbitone and so on) within 12 days before participating the study.
- •Pregnant or lactating women; fertile patients who are unwilling or unable to adopt effective contraceptives
- •Patients with mental sickness or the history of psychotropic drug abuse
- •Patients with severe infection (unable to control the infection effectively)
- •The treatment history affecting this program or its efficacy, such as stem cell transplantation, immune regulation (including PD-1 and other test regimens) recently (within half a year)
- •The researchers believe that any other factors unsuitable for entering into the study.
研究组 & 干预措施
One-drug Regimes
Experimental
Basic drug : Anlotinib Hydrochloride Capsules
干预措施: Anlotinib Hydrochloride Capsules (Drug)
Two-Drug Regimens
Experimental
Basic drug: Anlotinib Hydrochloride Capsules Add Intervention drug: Levamisole Hydrochloride
干预措施: Levamisole Hydrochloride (Drug)
Two-Drug Regimens
Experimental
Basic drug: Anlotinib Hydrochloride Capsules Add Intervention drug: Levamisole Hydrochloride
干预措施: Anlotinib Hydrochloride Capsules (Drug)
结局指标
主要结局
Progression-free Survival
时间窗: 24 months
Time from start of treatment until the first documented event of symptomatic progression or death.
次要结局
- Overall Survival(48 months)
研究者
Zujiang YU
The director of infectious diseases department
The First Affiliated Hospital of Zhengzhou University
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia.Anemia, HemolyticAnemia, Hemolytic, AutoimmuneHemolysisHematologic DiseasesAutoimmune DiseasesImmune System DiseasesPathologic ProcessesAnemiaNCT01579110Institute of Hematology & Blood Diseases Hospital, China100
已完成
2 期
Clinical Trial Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic PatientsOnchocerciasis, OcularLoiasisNCT04049630Programme National de Lutte contre l'Onchocercose, Republic of the Congo255
招募中
2 期
Evaluation of Levamisole efficacy in treatment of Covid-19IRCT20190810044500N7Yazd University of Medical Sciences50
已完成
2 期
The Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome (MDS) Associated With Del (5q) AbnormalityMyelodysplastic SyndromesNCT00874978King's College Hospital NHS Trust36
Unknown
3 期
Clinical Trials to Assess the Efficacy and Safety of HLIMAcute Upper Respiratory Tract InfectionAcute BronchitisNCT03827590SamA Pharmaceutical Co., Ltd487